Personalized Medicine – Products

A team of scientists led by the University of Oxford have achieved a significant breakthrough in detecting modifications on protein structures.

A landmark study demonstrates that precision oncology medicines could deliver a superior return on Investment for Pharma R&D vs their one size fits all counterparts.

Eremid® Genomic Services, LLC (“Eremid”) announces a significant expansion of its in-house sequencing capabilities with the installation of PacBio’s latest HiFi sequencing platform, the Revio.

Oncodesign Services announces the execution of a Preclinical License and Supply Agreement with ImaginAb Inc. for the use of their investigational CD8 ImmunoPET™ (89Zr crefmirlimab berdoxam) technology.

Identifying and optimizing the appropriate conditions for culturing organoids can be technically challenging. R&D Systems proteins are rigorously tested to ensure they will provide superior performance and lot-to-lot consistency to support robust, reproducible organoid cultures.

This application note outlines the importance of reagent consistency in organoid tissue culture.

New Kit Enables Automation of DNA Cloning on the BioXp® System Beginning from Linear DNA, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Molecular Biology Workstation.

Evosep proudly announces the release of End-to-End Proteomics Workflow.

Thermo Fisher Scientific Inc. (NYSE: TMO), unveiled the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer.

OncoHost has announced that it will give a poster presentation demonstrating the accuracy of its PROphet® biomarker model at the upcoming American Society of Clinical Oncology Annual Meeting, taking place June 2-6, 2023, in Chicago, Illinois.